TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Brief Summary: The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of study.


Options:
A: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
B: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: azithromycin and TIS; Type: ACTIVE_COMPARATOR; Interventions: Drug: azithromycin, Drug: Tobramycin solution for inhalation | Arm Label: placebo and TIS; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: Tobramycin solution for inhalation | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): azithromycin and TIS | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo and TIS | Intervention Type: DRUG; Name: Tobramycin solution for inhalation; Assigned to Arm(s): azithromycin and TIS, placebo and TIS

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Brief Summary: The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of study.


Options:
A: Arm Label: Cohort 1 - 280 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 1 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cohort 2 - 560 mg ARIKACE™; Type: EXPERIMENTAL; Interventions: Drug: ARIKACE™ | Arm Label: Cohort 2 - Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ARIKACE™; Assigned to Arm(s): Cohort 1 - 280 mg ARIKACE™, Cohort 2 - 560 mg ARIKACE™ | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 - Placebo, Cohort 2 - Placebo
B: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo three times a day (TID); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo three times a day (TID) | Arm Label: AZLI 75 mg three times a day (TID); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg three times a day (TID); Assigned to Arm(s): AZLI 75 mg three times a day (TID) | Intervention Type: DRUG; Name: Placebo three times a day (TID); Assigned to Arm(s): Placebo three times a day (TID)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Brief Summary: The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of study.


Options:
A: Arm Label: Cycled TOBI & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral placebo | Arm Label: Cycled TOBI & oral ciprofloxacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral ciprofloxacin | Arm Label: Culture based TOBI & placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral placebo | Arm Label: Culture based TOBI & oral cipro; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tobramycin solution for inhalation (TOBI), Drug: Oral ciprofloxacin | Intervention Type: DRUG; Name: Tobramycin solution for inhalation (TOBI); Assigned to Arm(s): Culture based TOBI & oral cipro, Culture based TOBI & placebo, Cycled TOBI & oral ciprofloxacin, Cycled TOBI & placebo | Intervention Type: DRUG; Name: Oral placebo; Assigned to Arm(s): Culture based TOBI & placebo, Cycled TOBI & placebo | Intervention Type: DRUG; Name: Oral ciprofloxacin; Assigned to Arm(s): Culture based TOBI & oral cipro, Cycled TOBI & oral ciprofloxacin
B: Intervention Type: DRUG; Name: tobramycin; Assigned to Arm(s): N/A
C: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
D: Arm Label: AZLI then Standard Care; Type: EXPERIMENTAL; Interventions: Drug: Aztreonam, Drug: Standard Care | Arm Label: Standard Care then AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aztreonam, Drug: Standard Care | Intervention Type: DRUG; Name: Aztreonam; Assigned to Arm(s): AZLI then Standard Care, Standard Care then AZLI | Intervention Type: DRUG; Name: Standard Care; Assigned to Arm(s): AZLI then Standard Care, Standard Care then AZLI

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Brief Summary: The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of study.


Options:
A: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A
B: Arm Label: Aeroquin 240 mg; Type: EXPERIMENTAL; Interventions: Drug: Aeroquin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aeroquin; Assigned to Arm(s): Aeroquin 240 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: AZLI; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZLI, Drug: Tobramycin inhalation solution | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match AZLI, Drug: Tobramycin inhalation solution | Intervention Type: DRUG; Name: AZLI; Assigned to Arm(s): AZLI | Intervention Type: DRUG; Name: Placebo to match AZLI; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Tobramycin inhalation solution; Assigned to Arm(s): AZLI, Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerbations in Patients With Cystic Fibrosis
Brief Summary: The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of study.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: MP-376 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Arm Label: MP-376 240 mg BID; Type: EXPERIMENTAL; Interventions: Drug: MP-376 | Intervention Type: DRUG; Name: MP-376; Assigned to Arm(s): MP-376 120 mg QD, MP-376 240 mg BID, MP-376 240 mg QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Observational; Type: N/A; Interventions: N/A
C: Arm Label: Tobramycin 300 mg for 28 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Arm Label: Tobramycin 300 mg for 56 days; Type: EXPERIMENTAL; Interventions: Drug: Tobramycin solution for inhalation 300 mg | Intervention Type: DRUG; Name: Tobramycin solution for inhalation 300 mg; Assigned to Arm(s): Tobramycin 300 mg for 28 days, Tobramycin 300 mg for 56 days
D: Arm Label: CF patients with pulmonary exacerbations; Type: N/A; Interventions: N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Patient Activation Tool in Pediatric Appendicitis to Determine Choice Between Antibiotics Alone vs. Appendectomy
Brief Summary: The purpose of this study is to determine if a patient activation tool (PAT) can improve decision making and patient centered outcomes in pediatric patients with appendicitis and their caregivers choosing between antibiotics alone and appendectomy.


Options:
A: Arm Label: Heart disease; Type: N/A; Interventions: N/A | Arm Label: Healthy adults; Type: N/A; Interventions: N/A
B: Arm Label: Decision Aid; Type: OTHER; Interventions: Other: Decision Aid | Arm Label: Standard; Type: OTHER; Interventions: Other: Standard | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision Aid | Intervention Type: OTHER; Name: Standard; Assigned to Arm(s): Standard
C: Arm Label: Patient Activation Tool; Type: EXPERIMENTAL; Interventions: Other: Patient Activation Tool | Arm Label: Standard Consultation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient Activation Tool; Assigned to Arm(s): Patient Activation Tool
D: Arm Label: One-on-one counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Arm Label: Web counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle and medication intervention | Intervention Type: BEHAVIORAL; Name: Lifestyle and medication intervention; Assigned to Arm(s): One-on-one counseling, Web counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Brief Summary: This research study is designed to assess the safety and effectiveness of an experimental drug called PRT-201 in patients both receiving or expecting to receive dialysis who have chronic kidney disease and who are undergoing surgery to create a new access point to their bloodstream for hemodialysis. PRT-201 is a protein that has been shown in previous research studies to help keep vessels patent when applied to the outside surface of the blood vessels (arteries and veins) in patients who undergo surgery to create an arteriovenous fistula (AVF). The purpose of this study is to determine whether PRT-201 when applied to a limited segment of your blood vessel (about 2 inches) immediately after surgery is safe and improves the patency of your AVF.


Options:
A: Arm Label: AV fistula with VasQ; Type: EXPERIMENTAL; Interventions: Device: VasQ | Arm Label: AV fistula; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: VasQ; Assigned to Arm(s): AV fistula with VasQ
B: Arm Label: PRT-201; Type: ACTIVE_COMPARATOR; Interventions: Drug: PRT-201 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: GTN patch; Type: EXPERIMENTAL; Interventions: Drug: GTN patch | Arm Label: Placebo patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo comparator | Intervention Type: DRUG; Name: GTN patch; Assigned to Arm(s): GTN patch | Intervention Type: DRUG; Name: placebo comparator; Assigned to Arm(s): Placebo patch
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: PRT-201; Type: EXPERIMENTAL; Interventions: Drug: PRT-201 | Intervention Type: DRUG; Name: PRT-201; Assigned to Arm(s): PRT-201 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Medically Ill Patient Assessment of Rivaroxaban Versus Placebo in Reducing Post-Discharge Venous Thrombo-Embolism Risk
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in high-risk, medically ill patients.


Options:
A: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban, 10 mg, Drug: Rivaroxaban, 7.5 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban, 10 mg; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Rivaroxaban, 7.5 mg; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Therapeutic dose low-molecular-weight heparin (LMWH); Type: ACTIVE_COMPARATOR; Interventions: Drug: low-molecular-weight heparin | Arm Label: D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy; Type: EXPERIMENTAL; Interventions: Drug: low-molecular-weight heparin | Intervention Type: DRUG; Name: low-molecular-weight heparin; Assigned to Arm(s): D-dimer levels and weight adjusted low-molecular-weight heparin (LMWH)therapy, Therapeutic dose low-molecular-weight heparin (LMWH)
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing the Burden of Depression on Employment: Improving Function and Work
Brief Summary: The purpose of this research study is to test the effectiveness of a new telephone counseling program for employed Veterans with depression called the Veterans Work and Health Initiative (V-WHI) using the Be Well at Work (BWAW) intervention. 250 participants will be recruited and randomly assigned to one of two groups: the V-WHI experimental group or usual mental health care. The V-WHI counselors will address mental health and job-related issues that interfere with working. This counseling is provided solely over the phone with sessions every 2 weeks for 4 months (eight sessions total). At 8 months post-baseline, the V-WHI group is provided with a booster session. Participants in both groups are administered follow-up questionnaires at two time-points: month four and month nine.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Enhancement Program and medication management | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Health Enhancement Program and medication management; Assigned to Arm(s): 2
B: Arm Label: Be Well At Work intervention + IC; Type: EXPERIMENTAL; Interventions: Other: Veterans Work and Health Initiative | Arm Label: Integrated Care Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Veterans Work and Health Initiative; Assigned to Arm(s): Be Well At Work intervention + IC
C: Arm Label: MoodHacker; Type: EXPERIMENTAL; Interventions: Behavioral: MoodHacker | Arm Label: Alternative Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Alternative Care | Intervention Type: BEHAVIORAL; Name: MoodHacker; Assigned to Arm(s): MoodHacker | Intervention Type: BEHAVIORAL; Name: Alternative Care; Assigned to Arm(s): Alternative Care
D: Intervention Type: BEHAVIORAL; Name: Endurance training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Weight-lifting training; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Thinking Healthy Program - Peer Delivered in Pakistan
Brief Summary: The rates of perinatal depression in South Asian women are reported to be amongst the highest in the world, ranging from 18%-30% in urban areas and 28%-36% in rural areas. In addition to its profound impact on women's health, disability and functioning, perinatal depression is associated with poor child health outcomes such as pre-term birth, infant under-nutrition and stunting. There is robust evidence that perinatal depression can be effectively managed with psychological treatments delivered by non-specialist health care workers. Our previous research conducted in Pakistan led to the development of the Thinking Healthy Program (THP). THP is a psychological treatment delivered by community health workers (CHWs) which more than halved the rate of perinatal depression among mothers and led to significant improvements in child health outcomes. To enhance access to such evidence-based psychological treatments, there is a need to examine the potential role of other human resources such as lay persons in delivering psychological treatments such as THP in poor resource settings.


Options:
A: Arm Label: Empateach Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Empateach | Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Empateach; Assigned to Arm(s): Empateach Intervention
B: Arm Label: Obese patients treated with bariatric surgery; Type: EXPERIMENTAL; Interventions: Procedure: Bariatric surgery | Arm Label: Obese patients not treated with bariatric surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Obese patients treated with bariatric surgery
C: Arm Label: Enhanced Usual Care (EUC); Type: OTHER; Interventions: Other: EUC | Arm Label: THPP-P; Type: EXPERIMENTAL; Interventions: Behavioral: THPP-P, Other: EUC | Intervention Type: BEHAVIORAL; Name: THPP-P; Assigned to Arm(s): THPP-P | Intervention Type: OTHER; Name: EUC; Assigned to Arm(s): Enhanced Usual Care (EUC), THPP-P
D: Arm Label: Mentor Mothers Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Peer support and mentoring | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Peer support and mentoring; Assigned to Arm(s): Mentor Mothers Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Patient-centered Care Transitions in Heart Failure: A Pragmatic Cluster
Brief Summary: Heart failure (HF) is the most common cause of hospitalization in older adults. The month after hospital discharge represents a vulnerable period, when patients are at increased risk of death and readmission to hospital. Research has shown that certain discharge-planning services can reduce death and readmissions, but these have not been widely implemented. In this study, we will group evidence-informed discharge-planning services into 'Patient-centered Care Transitions in HF' (PACT-HF), a model of care that will prepare patients for their transition from hospital to home. Through PACT-HF, patients will benefit from a comprehensive assessment of their health care needs, learn to recognize and manage symptoms of HF, and receive the information and follow-up care needed to optimize their health. We will introduce PACT-HF to 10 Ontario hospitals over a number of time periods using a stepped wedge cluster trial design. We will compare the outcomes (hierarchically ordered) of patients in hospitals with PACT-HF to those in hospitals without PACT-HF. We anticipate that patients hospitalized at the sites with PACT-HF will have fewer readmissions, emergency visits, and deaths after discharge; report a better quality of life; and feel more prepared for discharge. We also anticipate that overall, PACT-HF will reduce health system costs.


Options:
A: Arm Label: Telerehabilitation programme; Type: EXPERIMENTAL; Interventions: Device: Telerehabilitation programme | Arm Label: Control group traditional rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telerehabilitation programme; Assigned to Arm(s): Telerehabilitation programme
B: Arm Label: Discharge planning services; Type: ACTIVE_COMPARATOR; Interventions: Other: PACT-HF Model | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: PACT-HF Model; Assigned to Arm(s): Discharge planning services
C: Arm Label: Women-Only Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Co-ed Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Arm Label: Home-Based Cardiac Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cardiac Rehabilitation | Intervention Type: BEHAVIORAL; Name: Cardiac Rehabilitation; Assigned to Arm(s): Co-ed Cardiac Rehabilitation, Home-Based Cardiac Rehabilitation, Women-Only Cardiac Rehabilitation
D: Arm Label: Intervention; Type: N/A; Interventions: Behavioral: Intervention | Arm Label: Usual Care; Type: N/A; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Intervention; Assigned to Arm(s): Intervention

Answer: B